Another checkpoint inhibitor (tremelimumab) developed for targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) also showed promising clinical results for treating HCC patients [52]. Here, CTLA4 is linked to hepatocellular carcinoma.